PathAI Welcomes Mary Padilla, M.D., to Lead Clinical Development Services for Biopharma

Dr. Padilla brings a wealth of experience in pathology and drug development

BOSTON, May 16, 2024 —PathAI, a leading provider of AI-powered technology, announces that Mary Padilla, M.D., joins PathAI as Senior Vice President, Pathology & Clinical Development Services to lead Clinical Development Services for Biopharma.

Dr. Padilla will spearhead the expansion efforts of PathAI's clinical development services business, overseeing the integration of biopharma lab services, digital pathology, and AI technologies, as well as leveraging pathologist expertise to support prospective clinical studies in the pharmaceutical and biotechnology sectors. PathAI's GCP/CLIA certified laboratory in Memphis, TN, serves as the hub for lab services, while the company also offers laboratory and digital pathology services for translational research.

A pathologist by training, Dr. Padilla was most recently Executive Director, Translational Pathology at Pfizer following the acquisition of Seagen where she led Laboratory Operations. She is experienced in assay development, algorithm development, and diagnostic tools such as immunohistochemistry, in situ hybridization, and molecular technologies. Her extensive experience also includes a 3-year stint at Personal Genome Diagnostics and 9 years at Roche Tissue Diagnostics in various roles, including overseeing the dedicated Pathology group for the CDx lifecycle responsible for biopharma assay development and testing.

"We are thrilled to welcome Mary to the PathAI Biopharma leadership team," announced Matt Grow, Chief Business Officer and President of PathAI's Biopharma Business. "Drawing from her extensive expertise in pathology and clinical development with leading organizations, Dr. Padilla is well-positioned to scale our organization. Her guidance will be instrumental in driving forward our clinical trials business into its next phase of expansion," he added.

Dr. Padilla is highly regarded for delivering high-quality, compliant results, and fostering collaborations across and between functions and organizations.

About PathAI
PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples, with the potential to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI is headquartered in Boston, MA. For more information, please visit www.pathai.com.